Re: BofA Initiates Coverage on Novavax with an Underperform Rating, PT $35
I would suspect that Novavax would be a target acquisition at some point this year. Those inept fools cannot monetize anything.
But I think that $5-$10 B recurring revenue of the global NVAX product lines are attainable, reasonable, & realistic - but that’s likely only to be the case if the IB factors that all those fools are OUT & replaced via acquisition. Otherwise- maybe $4-$5B annually due to these events:
(i) Deliver all APA doses (2022-2023); &
(ii) Global booster market annually, coupled with
(iii) Licensing royalties fee income (SII, SK Bio, Takeda) - India’s 1.3-1.4B would probably utilize NVAX as the preferred booster for at least 30-40% of its population- so that alone @$9-10/dose would be significant revenue/income; &
(iv) Combo vaccine market annually (probably according to those slow fools) during 2025; &
(v) Praha deliveries, once begun probably by YE-2022 continue to grow throughout Europe & delivery points globally